Published in Drug Week, October 27th, 2006
This finding represents a significant advance by PharmaGap in the development of a commercializable cancer drug.
Dr. David Barnes, M.D., drug development advisor to the company, said, "This result is a major success for PharmaGap's development program for PhGalpha1. We now see that the compounds can be administered in a clinically relevant manner to a living animal subject, a well-recognized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.